Robust Virus-Specific Adaptive Immunity in COVID-19 Patients with SARS-CoV-2 Δ382 Variant Infection
SARS-CoV-2 Δ382 변이 감염이 있는 COVID-19 환자의 강력한 바이러스 특이적 적응 면역
Original Article
Published on
Journal: Journal of Clinical Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 치료기술, 치료제,
Journal: Journal of Clinical Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 치료기술, 치료제,
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
Adaptive immune response
Antibody Response
CD4+ T cell response
CD8+ T cell response
coronavirus
correlated
COVID-19
COVID-19 patients
Cytokines
disease phenotype
dominant
enrichment
eukaryotic
eukaryotic initiation factor 2
evidenced
host immunity
Host–pathogen interaction
identify
immune
immune signature
Immunity
initiation factor
less
molecular
Mutation
nucleotide deletion
ORF7b
ORF8
pandemic progresse
Patient
pro-inflammatory cytokines
profile
provide
Region
respiratory
RNA-sequencing
robust
SARS-CoV-2
SARS-CoV-2 infected patient
SARS-COV-2 infection
SARS-CoV-2 variant
severe acute respiratory syndrome Coronavirus
Signaling
spike mutations
supplementary material
systemic inflammation
systemic level
T cell
therapeutic target
Transcriptome
upregulated
variants of concern
VOCs
was performed
whole blood transcriptomic
wildtype
Δ382
[DOI] 10.1007/s10875-021-01142-z PMC 바로가기 [Article Type] Original Article
[DOI] 10.1007/s10875-021-01142-z PMC 바로가기 [Article Type] Original Article